Zobrazeno 41 - 50
of 152
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Jianli Zhao, Zhixian Sun, Yunfang Yu, Zhongyu Yuan, Ying Lin, Yujie Tan, Xiaohui Duan, Herui Yao, Ying Wang, Jieqiong Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006514
BackgroundImmune checkpoint inhibitors (ICIs)-based therapy, is regarded as one of the major breakthroughs in cancer treatment. However, it is challenging to accurately identify patients who may benefit from ICIs. Current biomarkers for predicting th
Autor:
Qianyi Lu, Ruoxi Hong, Wen Xia, Kuikui Jiang, Chenge Song, Zhongyu Yuan, Yuyu Ma, Fangfang Duan, Xiwen Bi, Jia Jia Huang, Fei Xu, Shusen Wang, Zhangzan Huang
Publikováno v:
Drug Design, Development and Therapy
Fangfang Duan,* Chenge Song,* Yuyu Ma, Kuikui Jiang, Fei Xu, Xiwen Bi, Jiajia Huang, Ruoxi Hong, Zhangzan Huang, Qianyi Lu, Zhongyu Yuan, Shusen Wang, Wen Xia Departments of Medical Oncology, Sun Yat-sen University Cancer Center, The State Ke
Publikováno v:
2022 8th International Conference on Mechanical Engineering and Automation Science (ICMEAS).
Autor:
Yousheng Mo, Wei Liu, Piaoxue Liu, Qiao Liu, Zhongyu Yuan, Qi Wang, Dongsheng Yuan, Xiao-Jia Chen, Tongkai Chen
Publikováno v:
International journal of nanomedicine. 17
Yousheng Mo,1,* Wei Liu,2,* Piaoxue Liu,2 Qiao Liu,3 Zhongyu Yuan,4 Qi Wang,2 Dongsheng Yuan,2 Xiao-Jia Chen,3 Tongkai Chen2 1The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, Peopleâs Republi
Autor:
Shangwen Jing, Yantong Lu, Jing Zhang, Yan Ren, Yousheng Mo, Dongdong Liu, Lining Duan, Zhongyu Yuan, Changjun Wang, Qi Wang
Publikováno v:
Drug design, development and therapy. 16
Shangwen Jing,1,* Yantong Lu,1,2,* Jing Zhang,1 Yan Ren,1,2 Yousheng Mo,3 Dongdong Liu,3 Lining Duan,4 Zhongyu Yuan,5 Changjun Wang,2 Qi Wang1 1Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Peo
Publikováno v:
Ann Transl Med
BACKGROUND: Attributed to inter-tumor heterogeneity, the therapeutic effect of salvage treatment is diverse and different malignant lesions might manifest various therapeutic responses among advanced breast cancer (ABC) patients. The present study ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c476031bacb70e64548f6afb7e73ec5
https://europepmc.org/articles/PMC9201163/
https://europepmc.org/articles/PMC9201163/
Publikováno v:
Cancer Research. 83:P5-02
Introduction: Immunotherapy, especially immune checkpoint inhibitors, is regarded as one of the major breakthroughs in breast cancer treatment. However, it is an important challenge to accurately locate the patients who benefit from immunotherapy, be
Autor:
Fei Xu, Kaping Lee, Shusen Wang, Qianyi Lu, Jin Wei, Kuikui Jiang, Xin An, Wen Xia, Liye Wang, Ruoxi Hong, Jinquan Yu, Weijia Tang, Zhongyu Yuan, Jia Jia Huang, Shengfeng Li, Cong Xue, Xiwen Bi, Danyang Zhou, Yanxia Shi
Publikováno v:
Cancer Communications, Vol 41, Iss 2, Pp 171-182 (2021)
Cancer Communications
Cancer Communications
Background The introductions of anti‐ human epidermal growth factor receptor‐2 (HER2) agents have significantly improved the treatment outcome of patients with HER2‐positive breast cancer. BAT8001 is a novel antibody‐drug conjugate targeting
Autor:
Zhongyu Yuan, Quchang Ouyang, Fei Xu, Roujun Peng, Shusen Wang, Danmei Pang, Yanxia Shi, Wen Xia, Qiufan Zheng, Qianyi Lu
Publikováno v:
Oncologist
Lessons Learned Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression-free survival of 16.1 months in patients who achieved objective responses or disease control after first-line chemotherapy. Adverse ev
Autor:
Zhongyu Yuan, Chenge Song, Zhangzan Huang, Jia Jia Huang, Zhen-Yu He, Xin Hua, Wen Xia, Xiwen Bi
Publikováno v:
Gland Surg
BACKGROUND: Breast cancer is one of the most common malignancy in women with high mortality rate. Given the growing evidence shows that immune-inflammatory system influences the survival of patients with cancer, we assessed the prognostic significanc